Difficulties and inequities in access to homologous recombination deficiency testing in ovarian cancer patients

Ovarian cancer; HRD; Inequity; Access

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] AIOM-AIRTUM. The numbers of cancer in Italy. 2023. Available at: https://www.aiom.it/wp-content/uploads/2023/12/2023_AIOM_NDC_def.pdf (Accessed: 14 December 2023).

[3] Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, et al. Cell origins of high-grade serous ovarian cancer. Cancers. 2018; 10: 433.

[4] Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. New England Journal of Medicine. 2019; 381: 2403–2415.

[5] González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine. 2019; 381: 2391–2402.

[6] Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. New England Journal of Medicine. 2019; 381: 2416–2428.

[7] Swisher EM, Aghajanian C, O’Malley DM, Fleming GF, Kaufmann SH, Levine DA, et al. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic Oncology. 2022; 164: 245–253.

[8] LYNPARZAÒ. Highlights of prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf (Accessed: 8 May 2020).

[9] EMA Lynparza. Summary of opinion. Post authorization. 2017. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-lynparza-ii-35-ii-36_en.pdf (Accessed: 18 September 2020).

[10] AIFA Lynparza. Reimbursement approval. 2023. Available at: https://www.aifa.gov.it/documents/20142/961234/Determina_194-2022_Lynparza.pdf (Accessed: 18 March 2022).

[11] Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology. 2022; 33: 276–287.

[12] Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology. 2020; 31: 1606–1622.

[13] Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discovery. 2015; 5: 1137–1154.

[14] Weichert W, Lukashchuk N, Yarunin A, Riva L, Easter A, Bannister H, et al. An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer. International Journal of Gynecological Cancer. 2021; 31: A1–A395.

[15] Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, et al. Locally performed HRD testing for ovarian cancer? Yes, we can! Cancers. 2022; 15: 43.

[16] Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica. 2022; 114: 288–294.

[17] Kekeeva T, Andreeva Y, Tanas A, Kalinkin A, Khokhlova S, Tikhomirova T, et al. HRD testing of ovarian cancer in routine practice: what are we dealing with? International Journal of Molecular Sciences. 2023; 24: 10497.

[18] Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J, et al. Access and quality of biomarker testing for precision oncology in Europe. European Journal of Cancer. 2022; 176: 70–77.

[19] ESGO Consortium of Accreditated Centers. Requirements for ESGO accreditation & re-accreditation of European Training Centres in Gynaecological Oncology. 2023. Available at: https://esgo.org/media/2023/04/Requirements-for-Accreditation-Training-Centres-2023.pdf (Accessed: 24 April 2023).

[20] European Cancer Patient Coalition. Realising the potential of genomic technologies in cancer care. 2021. Available at: https://ecpc.org/wp-content/uploads/2021/12/Report-Realising-the-potential-of-genomic-technologies-in-cancer-care-2021.pdf. (Accessed: 7 December 2021).

[21] European Commission, Directorate-General for Employment, Social Affairs and Inclusion, McGrath J. Analysis of shortage and surplus occupations 2020, Publications Office of the European Union. 2020. Available at: https://data.europa.eu/doi/10.2767/933528 (Accessed: 28 March 2023).